NEW ORLEANS, July 26, 2011 /PRNewswire/ — NuMe Health LLC, a
biotechnology company developing evidence-based prebiotics designed
to address specific health conditions, today announced that it has
closed a series A-1 financing round and hired Dean P. Stull, PhD,
as chief executive officer. The $675,000 financing was led by
BVM Capital LLC and represents the first closing of a larger series
A round. The funds from the financing will be used primarily to
support corporate and product development as the company prepares
to commercialize its first prebiotic products for the dietary
supplement and health food markets.
“The closing of this venture financing is an important milestone
for NuMe Health that should enable us to accelerate the development
and launch of our first prebiotic products,” said Dr. Stull.
“This is an exciting time as scientists are uncovering the
critical role that the bacteria which co-exist in our bodies play
in health and disease. NuMe intends to be a leader in
developing novel evidence-based prebiotic products to help prevent
and manage common diseases, initially targeting conditions
involving metabolism and the maintenance of healthy body
weight.”
Prebiotics are based on scientists’ rapidly expanding knowledge
of how the microbiome–the large population of microbes, their
genomes and the interactions between them within the GI tract–can
significantly impact human health. Prebiotics are
non-digestible ingredients that serve as nutrients for beneficial
GI bacteria. Unlike probiotics, which attempt to add certain
microbes to the GI tract, prebiotics work primarily by providing
the nutrition that these beneficial microbes need to grow and
thrive. Since the huge number of microbes in the GI tract can
overwhelm the relatively small amounts of bacteria contained in
probiotic supplements, many researchers believe that prebiotics may
have a more significant and lasting impact on health.
‘/>”/>
